Immunai CTO and Co-Founder Luis Voloch on Using Deep Learning to Develop New Drugs - Ep. 176
NVIDIA AI Podcast
00:00
The Future of Machine Learning at Imuni
Louise, i like to joke that now maybe from the top nong machine learning people maybel somewhere between one and five % will go into byology and rigt now. And i think in the next ten years, this number will go to like 30 or forty percent at the wi ad. So i can see the future. Job listing now wanted. Machine learning ere must be facile in pharmaceutical compounds. And you know, life science is preferably biology. It gets, the bar gets higher and higher as we go out anec end,. i think it will be a very sidig putation of ferrishinler people. Louise, there's a lot on your plate
Transcript
Play full episode
